Breast cancer immunotherapy using scFv antibody-based approaches, a systematic review

• Published in: Human immunology Vol. 85; no. 5; p. 111090
• Main Authors: Heidarnejad, Kamran, Nooreddin Faraji, Seyed, Mahfoozi, Shirin, Ghasemi, Zahra, Sadat Dashti, Fateme, Asadi, Maryam, Ramezani, Amin
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.09.2024
• Subjects: Breast cancer; Immunotherapy; scFv; Single-chain antibody; Single-chain antibody; Breast cancer; scFv; Immunotherapy
• ISSN: 0198-8859; 1879-1166; 1879-1166
• DOI: 10.1016/j.humimm.2024.111090

Breast cancer is considered as the most common malignancy in women and the second leading cause of death related to cancer. Recombinant DNA technologies accelerated the development of antibody-based cancer therapy, which is effective in a broad range of cancers. The objective of the present study was to perform a systematic review on breast cancer immunotherapy using single-chain fragment variable (scFv) antibody formats. Searches were performed up to March 2023 using PubMed, Scopus, and Web of Science (ISI) databases. Three reviewers independently assessed study eligibility, data extraction, and evaluated the methodological quality of included primary studies. Different immunotherapy approaches have been identified and the most common approaches were scFv-conjugates, followed by simple scFvs and chimeric antigen receptor (CAR) therapy, respectively. Among breast cancer antigens, HER superfamily, CD family, and EpCAM were applied as the most important breast cancer immunotherapy targets. The present study shed more lights on scFv-based breast cancer immunotherapy approaches.